YMYaser Masoumi-Ardakani

Yaser Masoumi-Ardakani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yaser Masoumi-Ardakani has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Beydolah Shahouzehi

    Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

    8 shared publications
  • Soheil Aminizadeh

    Department of Physiology and Pharmacology, Afzalipour school of Medicine, and Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

    4 shared publications
  • Hamid Najafipour

    Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

    3 shared publications
  • Hossein Fallah

    Department of Clinical Biochemistry, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran

    3 shared publications
  • Beydolah Shahouzehi

    Cardiovascular Research Center, Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

    2 shared publications
  • Hamid Reza Nasri

    Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

    2 shared publications

Latest Publications

  • Open Access

    Antioxidant Effects of Pioglitazone and Interleukin-1 receptor-associated kinase inhibitor on Oxidative Stress Indices in obese C57BL/6J Mice

    by Hossein Fallah, Yaser Masoumi-Ardakani, Mahtab Pourkamalzadeh, Beydolah Shahouzehi

    Background: Pioglitazone possesses antioxidant properties, whereas the antioxidant effects of IRAKi (Interleukin-1 receptorassociated kinase inhibitor; an anti-inflammatory agent) remain less established. Therefore, we investigated the antioxidant properties of IRAKi and pioglitazone in the liver of obese C57BL/6J mice. Methods: Thirty-five mice were randomly assigned to five groups (n=7); Control, high-fat diet (HFD), HFD-IRAKi, HFD-pioglitazone (PIO), and HFD-IRAKi-PIO. After 12 weeks on an HFD, IRAKi (2 mg/kg, intraperitoneally, three times a week) and pioglitazone (10 mg/kg, orally, daily) were administered for two weeks. The expression levels of Superoxide dismutase (SOD) and glutathione peroxidase (GPx) genes were evaluated through Real-time PCR analysis. Malondialdehyde (MDA), SOD, total antioxidant status (TAS), GPx, and total oxidant status (TOS) levels were quantified. Results: HFD increased oxidative stress. IRAKi and pioglitazone, administered separately, increased SOD and TAS while reducing MDA and TOS compared to the HFD group. However, neither treatment significantly altered GPx activity. The combination of IRAKi and pioglitazone exhibited superior antioxidant effects compared to their separate administrations. Specifically, the combined treatment improved both GPx and SOD levels as well as their gene expression. Conclusion: Our findings demonstrate the antioxidative effects of IRAKi and pioglitazone in C57BL/6J mice. Notably, their combination produced additive effects, enhancing the antioxidant defense system in the liver. These results suggest that IRAKi and pioglitazone, when used together, may serve as a promising therapeutic approach for managing oxidative stress in liver disease. By providing a dual mechanism of action, this combination highlights its potential for broader clinical applications in chronic disease management.


  • Open Access

    Exploring serum miR-33b as a novel diagnostic marker for hypercholesterolemia and obesity: insights from a pilot case-control study

    by Yaser Masoumi-Ardakani, Mostafa Eghbalian, Hossein Fallah, Alireza Jafari, Beydolah Shahouzehi

    Obesity and atherosclerosis are significant metabolic diseases characterized by disrupted lipid metabolism. MicroRNAs (miRNAs) are small, conserved, non-coding RNA sequences consisting of approximately 22 nucleotides, playing crucial roles in biological and pathological functions. Among these, miR-33a/b is particularly associated with metabolic diseases, notably obesity and atherosclerosis. In this pilot case-control study, 45 subjects were examined, and serum miR-33b levels were measured in three groups: a control group, hypercholesterolemic (HC) subjects without obesity (HC group), and obese subjects without hypercholesterolemia (obese group). Serum miR-33b levels were determined using the real-time PCR method. The expression of miR-33b was significantly higher in the HC and obese groups compared to the control group (p < 0.001). The Body mass index (BMI) in the obese group was significantly higher than in the control and HC groups (p < 0.001). Additionally, serum total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-c) levels were higher in the HC group compared to both the control and obese groups. Our study demonstrated a correlation between serum miR-33b levels and HC and obesity. Finally, the ROC analysis demonstrated that miR-33b had an AUC of 0.74 for identifying hypercholesterolemia and an AUC of 0.76 for identifying obesity, indicating its acceptable diagnostic value alongside traditional markers. Therefore, serum miR-33b levels can be considered as a potential biomarker for obesity and hypercholesterolemia, but these finding are preliminary and further investigation is necessary in larger samples to confirm these associations.


  • Open Access

    Concomitant L-Carnitine Supplementation and Exercise Training Affects Apoptosis in Male Rats

    by Beydolah Shahouzehi, Banafsheh Daneshmand, Mahdieh Nazari-Robati, Soheil Aminizadeh, Yaser Masoumi-Ardakani

    Background: Apoptosis is a defensive measure that removes dysfunctional cells. Exercise training has a broad spectrum of benefits that influence apoptosis and cell viability. L-carnitine (LCAR), a supplement nowadays, has shown beneficial effects against cell death. We investigated the simultaneous effect of exercise training (acute exercise [AE] and high-intensity interval training [HIIT]) and LCAR supplementation on the proteins involved in apoptosis. The animals were anesthetized twenty-four hours after the conclusion of the final training session. Methods: Forty-eight male Wistar rats (210±10 g) were assigned to six groups (n=8) as follows: Control, LCAR (200 mg/kg/d LCAR, IP), AE, HIIT, LCAR+AE, and LCAR+HIIT. The animals were anesthetized and sacrificed twenty-four hours after the last training session; the rats’ blood sample was collected, and the serum was separated. The serum Bcl-2 levels, as an anti-apoptotic factor, and caspase-3 and BAX, as proapoptotic factors, were measured using specific ELISA kits. Results: AE increased apoptosis, but HIIT’s effects were almost neutral. LCAR administration in groups that performed either AE or HIIT significantly attenuated apoptosis. However, in group 6 (LCAR+HIIT), the anti-apoptotic effects were noteworthy because LCAR+HIIT significantly increased Bcl-2 and reduced caspase-3 levels compared to the control group. Conclusion: HIIT improved cell viability through increasing Bcl-2 levels, and LCAR strengthened HIIT’s anti-apoptotic properties. AE increased proapoptotic proteins, and LCAR modified the elevated proapoptotic markers in the AE group. Therefore, LCAR may be considered a promising supplement against exercise-mediated injury. This study can be extended to humans to evaluate the beneficial effects of LCAR+HIIT and LCAR+AE.

  • Open Access

    Association of ERCC1 Gene Polymorphisms (rs3212986 and rs11615) With the Risk of Lung Cancer in a Population From Southeast Iran

    by Ali Khalouei, Yaser Masoumi-Ardakani, Abdollah Jafarzaheh, Behjat Kalantari Khandani, Farnaz Sedghy, Arezu Khosravi Mashizi, Mohammad Mehdi Yaghoobi, Mohammadreza Zangouey, Beydolah Shahouzehi

    Background: Polymorphisms within the excision repair cross-complementation group 1 (ERCC1), an essential component of DNA repair mechanisms, have been associated with various malignancies. This study aimed to evaluate the association of the single-nucleotide polymorphisms (SNPs) rs3212986 and rs11615 within the ERCC1 gene in non-small cell lung cancer (NSCLC) patients. Study Design: A case-control study. Methods: Genomic DNA was extracted from the peripheral blood samples of 83 NSCLC patients and 119 healthy individuals. The genetic diversity of SNPs rs3212986 and rs11615 was determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The RFLP results were confirmed through sequencing. Results: The TT genotype of the rs11615 SNP was associated with a higher risk of NSCLC development (odds ratio: 3.900, 95% confidence interval: 0.603, 22.866, P=0.050). Furthermore, the AA genotype of rs3212986 was related to a higher risk of NSCLC development (OR: 2.531, 95% CI: 1.017, 6.300, P=0.046). A significant association was observed between smoking and lung cancer (OR: 3.072, 95% CI: 1.715, 5.503, P<0.001). Moreover, among non-smokers, there was an association between lung cancer risk and the AA (OR: 6.825, 95% CI: 1.722, 27.044, P=0.006) and AC (OR: 2.503, 95% CI: 0.977, 6.412, P=0.056) genotypes of rs3212986. However, no correlation was found between the genotypes of these SNPs and patients’ sensitivity to cisplatin and carboplatin (P ˃ 0.05). Conclusion: The rs11615-related TT genotype and the rs3212986-related AA genotype may be associated with a higher risk of lung cancer development.


  • Open Access

    Circulatory miR-133a and miR-145 are Associated with the Improving Impact of Combined Endurance Exercise and MitoQ on Cardiovascular Function in Patients with Hypertension

    by Yaser Masoumi-Ardakani, Hamid Najafipour, Hamid Reza Nasri, Beydolah Shahouzehi, Najmeh Noohi

    We used mitoquinone (MitoQ), a mitochondria-targeted antioxidant, alone and combined with moderate ET (endurance training) in male patients with hypertension to determine their effects on blood pressure (BP), cardiac function, TOS (total oxidant status), and serum miR-145, miR-133a, and hs-CRP levels. Moderately HTN patients participated in groups of Placebo, MitoQ, ET, and MitoQ+ET. Serum was used to assess miR-133a, miR-145, TOS, and hs-CRP, and echocardiography was performed to assess cardiac performance. In the MitoQ+ET group, BP, left ventricular hypertrophy, and cardiac filling pressure decreased. Ejection fraction did not change significantly. Both MitoQ+ET and ET significantly reduced TOS and hs-CRP and significantly increased miR-145 and miR-133a in serum. Overall anti-inflammatory and antioxidant properties of ET and MitoQ were associated with miR-145 and miR-133a increase, and with cardiac function and BP improvements in patients with HTN. MitoQ+ET may potentially be used as an alternative therapy in HTN treatment.

  • Open Access

    Effect of Combined Endurance Training and MitoQ on Cardiac Function and Serum Level of Antioxidants, NO, miR‐126, and miR‐27a in Hypertensive Individuals

    by Yaser Masoumi-Ardakani, Hamid Najafipour, Hamid Reza Nasri, Soheil Aminizadeh, Shirin Jafari, Daruosh Moflehi

    Objectives. Hypertension (HTN) is one of the most important risk factors for cardiovascular diseases. Despite advances in treatment and control of HTN, the prevalence of HTN is still increasing. MitoQ is a supplement that acts on mitochondria and attenuates reactive oxygen species (ROS), which plays an important role in cardiovascular health. miRNAs play an important role in the pathophysiology of HTN. We evaluated the effects of MitoQ supplementation and endurance training (ET), alone and in combination, on functional indices of the heart and serum levels of miR‐126, miR‐27a, antioxidants, and NO, in patients with HTN. Methods. In a double‐blind randomized clinical trial, 52 male participants (age 40‐55 years) were randomly divided into four groups (n = 13) of placebo, MitoQ (20 mg/day, oral), ET (cycle ergometer, moderate intensity, 40‐60% VO2 peak, heart rate 120‐140 b/min, 45 min a day, three days/week for six weeks), and MitoQ+ET. Cardiac function indices were assessed by echocardiography before and after interventions. Results. Systolic blood pressure (SBP) significantly decreased in all intervention groups (P < 0.001) while DBP (P < 0.01) and LV hypertrophy (P < 0.05) were significantly decreased only in the MitoQ+ET group. Serum levels of SOD, GPx, and NO and the level of miR‐126 significantly increased in all treatment groups, while miR‐27a reduced in the ET (P < 0.05) and MitoQ+ET (P < 0.01) groups. Conclusions. Compared to MitoQ and ET alone, their combination has more prominent improving effects on cardiac health and amelioration of BP in the patients with HTN. These effects are through miR‐126 and miR‐27a modulation and ameliorating mitochondrial ROS production.


  • Serum microRNA-33 levels in pre-diabetic and diabetic patients

    by Beydolah Shahouzehi, Mostafa Eghbalian, Hossein Fallah, Soheil Aminizadeh, Yaser Masoumi-Ardakani

    Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia and abnormal insulin secretion. MicroRNAs are small, non-coding RNAs that are able to affect cell biological functions and act as biomarkers for some diseases such as DM. In current study, we measured serum miR-33 in three groups (n = 15) as follows; non-diabetic control, pre-diabetic, and DM patients. Real-time PCR method was used to quantify miR-33 expression. miR-33 expression was significantly increased in pre-diabetic subjects compared to other two groups (p < 0.001). FBS (p < 0.001), insulin (p < 0.001), HOMA-IR (p < 0.001), and TG (p = 0.026) were higher in diabetic subjects than the other two groups. In people that had high physical activity, the number of diabetic subjects were zero and most of them were in pre-diabetic group (p = 0.019). Serum miR-33 level significantly and positively correlated with pre-diabetic state (B = 2.67, p = 0.000), Sex (B = 1.03, p = 0.025), and FBS (B = 0.04, p = 0.036) and also miR-33 was significantly and negatively correlated with HOMA-IR (B = − 1.58, p = 0.04). These findings support the possible role of miR-33 to monitor pre-diabetes onset and progression. It needs to be evaluated in future studies with high number of participants to clarify its mechanism and diagnostic viability.


  • Open Access

    Low‐Frequency Stimulation Prevents Kindling‐Induced Impairment through the Activation of the Endocannabinoid System

    by Sina Khajei, Khadijeh Esmaeilpour, Javad Mirnajafi-Zadeh, Vahid Sheibani, Soheila Rezakhani, Yaser Masoumi-Ardakani

    Background. Cannabinoid system affects memory and has anticonvulsant effects in epileptic models. In the current study, the role of cannabinoid 1 (CB1) receptors was investigated in amelioration of the effects of low‐frequency stimulation (LFS) on learning and memory impairments in kindled rats. Methods. Electrical stimulation of the hippocampal CA1 area was employed to kindle the animals. LFS was applied to the CA1 area in four trials following the last kindling stimulation. One group of animals received intraperitoneal injection of AM251 (0.1 μg/rat), a CB1 receptor antagonist, before the LFS application. Similarly, CB1 agonist WIN55‐212‐2 (WIN) was administrated to another group prior to LFS. The Morris water maze (MWM) and the novel object recognition (NOR) tests were executed 48 h after the last kindling stimulation to assess learning and memory. Results. Applying LFS in the kindled+LFS group restored learning and memory impairments in the kindled rats. There was a significant difference between the kindled and the kindled+LFS groups in learning and memory. The application of AM251 reduced the LFS effects significantly. Adversely, WIN acted similarly to LFS and alleviated learning and memory deficits in the kindled+WIN group. In addition, WIN did not counteract the LFS enhancing effects in the KLFS+WIN group. Conclusions. Improving effects of LFS on learning and memory impairments are mediated through the activation of the endocannabinoid (ECB) system.

  • Open Access

    The effect of different digoxin concentrations on heart tissue and antioxidant status in iron-overloaded rats

    by Beydolah Shahouzehi, Hamid Reza Nasri, Yaser Masoumi-Ardakani

    BACKGROUND: Thalassaemia is a hereditary disorder and has an economic burden on patients and the government. The most prevalent complication in these patients is iron overload which is followed by cardiomyopathy. Digoxin is considered as a treatment against heart failure in thalassaemia. The present study evaluated the effect of two digoxin concentrations on iron content and antioxidative defense in cardiac tissue of iron-overloaded rats. METHODS: The study was conducted on 48 rats which were divided into 6 groups. Group 1 was the control group and did not receive any treatment and group 2 was the iron overload group. In addition groups 3 and 4 were the digoxin control groups which received 1 and 5 mg/kg/day of digoxin, respectively. Groups 5 and 6 received 1 and 5 mg/kg/day of digoxin plus iron-dextran, respectively. After 1 month, malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPX), and total antioxidant status (TAS) were assessed in cardiac tissues. RESULTS: Co-administration of iron-dextran and digoxin (1 and 5 mg/kg/day) significantly increased SOD and TAS levels (P < 0.0010) and reduced MDA (P < 0.0010) in heart tissue compared to control and iron overload groups. GPX levels significantly reduced in groups 5 and 6 (iron + digoxin 1 (P < 0.0500) and iron + digoxin 5) (P < 0.0010) compared to the iron control group. CONCLUSION: Digoxin remarkably facilitates iron uptake by cardiomyocytes by affecting other channels such as L-type and T-type Ca2+ channels (LTCC and TTCC). Digoxin administration in the iron-overloaded rat model deteriorated antioxidative parameters and increased iron entry into heart tissue at higher doses. Therefore, in patients with beta thalassaemia major, digoxin must be administered with great care and serum iron and ferritin must be regularly monitored.